Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug interactions, of which the underlying mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisenmann, Eric D., Garrison, Dominique A., Talebi, Zahra, Jin, Yan, Silvaroli, Josie A., Kim, Jin-Gyu, Sparreboom, Alex, Savona, Michael R., Mims, Alice S., Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025810/
https://www.ncbi.nlm.nih.gov/pubmed/35456528
http://dx.doi.org/10.3390/pharmaceutics14040694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025810/
https://www.ncbi.nlm.nih.gov/pubmed/35456528
http://dx.doi.org/10.3390/pharmaceutics14040694

Ejemplares similares